WallStreetZenWallStreetZen

NASDAQ: ENGN
Engene Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for ENGN

Based on 6 analysts offering 12 month price targets for Engene Therapeutics Inc

Min Forecast
$2.00+14.29%
Avg Forecast
$10.58+504.74%
Max Forecast
$30.00+1,614.29%

Should I buy or sell ENGN stock?

Based on 6 analysts offering ratings for Engene Therapeutics Inc.

Buy
Strong Buy
0 analysts 0%
Buy
3 analysts 50%
Hold
3 analysts 50%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although ENGN's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates ENGN as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their ENGN stock forecasts and price targets.

ENGN stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-06-16
lockedlocked$00.00+00.00%2026-05-14
lockedlocked$00.00+00.00%2026-05-08
lockedlocked$00.00+00.00%2026-05-08
lockedlocked$00.00+00.00%2026-04-13
Oppenheimer
Top 4%
97
BuyMaintains$30.00+1,614.29%2026-03-11

1 of 1

Forecast return on equity

Is ENGN forecast to generate an efficient return?

Company
-27.58%
Industry
92.18%
Market
176.76%
ENGN's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is ENGN forecast to generate an efficient return on assets?

Company
-22.89%
Industry
27.58%
ENGN is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

ENGN earnings per share forecast

What is ENGN's earnings per share in the next 3 years based on estimates from 14 analysts?

Avg 1 year Forecast
-$2.03
Avg 2 year Forecast
-$2.00
Avg 3 year Forecast
-$1.47

ENGN revenue forecast

What is ENGN's revenue in the next 3 years based on estimates from 14 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$9.3M
Avg 3 year Forecast
$54.4M

ENGN vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ENGN$1.75$10.58+504.74%Buy
VRCA$6.84$12.00+75.44%Buy
PEPG$1.70$9.25+444.12%Strong Buy
GUTS$0.74$6.00+707.54%Buy
NTHI$4.58$16.00+249.34%Strong Buy
View Top Biotech Stocks

Engene Therapeutics Stock Forecast FAQ

Is Engene Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 6 Wall Street analysts covering (NASDAQ: ENGN) stock is to Buy ENGN stock.

Out of 6 analysts, 0 (0%) are recommending ENGN as a Strong Buy, 3 (50%) are recommending ENGN as a Buy, 3 (50%) are recommending ENGN as a Hold, 0 (0%) are recommending ENGN as a Sell, and 0 (0%) are recommending ENGN as a Strong Sell.

If you're new to stock investing, here's how to buy Engene Therapeutics stock.

What is ENGN's earnings growth forecast for 2026-2028?

(NASDAQ: ENGN) Engene Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.51%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.86%.

Engene Therapeutics's earnings in 2026 is -$126,850,000.On average, 14 Wall Street analysts forecast ENGN's earnings for 2026 to be -$136,209,681, with the lowest ENGN earnings forecast at -$162,811,198, and the highest ENGN earnings forecast at -$122,389,754. On average, 14 Wall Street analysts forecast ENGN's earnings for 2027 to be -$134,173,201, with the lowest ENGN earnings forecast at -$164,780,688, and the highest ENGN earnings forecast at -$91,440,621.

In 2028, ENGN is forecast to generate -$98,467,816 in earnings, with the lowest earnings forecast at -$157,559,224 and the highest earnings forecast at -$52,754,204.

What is ENGN's revenue growth forecast for 2026-2028?

(NASDAQ: ENGN) Engene Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.99%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.34%.

Engene Therapeutics's revenue in 2026 is $0.On average, 14 Wall Street analysts forecast ENGN's revenue for 2026 to be $0, with the lowest ENGN revenue forecast at $0, and the highest ENGN revenue forecast at $0. On average, 14 Wall Street analysts forecast ENGN's revenue for 2027 to be $620,858,371, with the lowest ENGN revenue forecast at $0, and the highest ENGN revenue forecast at $2,123,097,146.

In 2028, ENGN is forecast to generate $3,645,030,824 in revenue, with the lowest revenue forecast at $591,516,985 and the highest revenue forecast at $11,514,819,311.

What is ENGN's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: ENGN) forecast ROA is -22.89%, which is lower than the forecast US Biotechnology industry average of 27.58%.

What is ENGN's Price Target?

According to 6 Wall Street analysts that have issued a 1 year ENGN price target, the average ENGN price target is $10.58, with the highest ENGN stock price forecast at $30.00 and the lowest ENGN stock price forecast at $2.00.

On average, Wall Street analysts predict that Engene Therapeutics's share price could reach $10.58 by Jun 16, 2027. The average Engene Therapeutics stock price prediction forecasts a potential upside of 504.74% from the current ENGN share price of $1.75.

What is ENGN's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: ENGN) Engene Therapeutics's current Earnings Per Share (EPS) is -$2.17. On average, analysts forecast that ENGN's EPS will be -$2.03 for 2026, with the lowest EPS forecast at -$2.43, and the highest EPS forecast at -$1.83. On average, analysts forecast that ENGN's EPS will be -$2.00 for 2027, with the lowest EPS forecast at -$2.46, and the highest EPS forecast at -$1.37. In 2028, ENGN's EPS is forecast to hit -$1.47 (min: -$2.35, max: -$0.79).

What is ENGN's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: ENGN) forecast ROE is -27.58%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.